Skip to main content
. 2011 Mar 17;3(1):1426–1453. doi: 10.3390/cancers3011426

Figure 1.

Figure 1.

Epigenetics underpinning cisplatin resistance in NSCLC. Diagram summarizing the available evidence linking aberrant epigenetics in the forms of altered gene regulation, or how alterations to the levels of epigenetic modifiers may affect NSCLC sensitivity to cisplatin chemotherapies.